Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.44 |
| ▸ | CA2 | P00918 | 9/20 | 0.44 |
| ▸ | CA12 | O43570 | 7/20 | 0.44 |
| ▸ | CA9 | Q16790 | 7/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.40 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14287333 | 1.00 | CA1 (0.44) | CA1CA2CA12CA9MCL1 | |
| SCHEMBL5113914 | 1.00 | CA1 (0.44) | CA1CA2CA12CA9MCL1 | |
| SCHEMBL5111211 | 0.93 | PARK7 (0.48) | CA1CA2CA12CA9MCL1 | |
| SCHEMBL5111207 | 0.93 | PARK7 (0.48) | CA1CA2CA12CA9MCL1 | |
| SCHEMBL14287374 | 0.91 | PARK7 (0.41) | CA1CA2CA12CA9MCL1 | |
| SCHEMBL5118310 | 0.91 | PARK7 (0.41) | CA1CA2CA12CA9MCL1 | |
| SCHEMBL5113251 | 0.91 | PARK7 (0.41) | CA1CA2CA12CA9MCL1 | |
| SCHEMBL5111370 | 0.90 | PARK7 (0.40) | CA1CA2CA12CA9MCL1 | |
| SCHEMBL14287334 | 0.90 | PARK7 (0.40) | CA1CA2CA12CA9MCL1 | |
| SCHEMBL5111360 | 0.90 | PARK7 (0.40) | CA1CA2CA12CA9MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | claimed |
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | CA1 4882/4885CA2 4535/4885CA12 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.